These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 24018336)

  • 1. Linked clinical trials--the development of new clinical learning studies in Parkinson's disease using screening of multiple prospective new treatments.
    Brundin P; Barker RA; Conn PJ; Dawson TM; Kieburtz K; Lees AJ; Schwarzschild MA; Tanner CM; Isaacs T; Duffen J; Matthews H; Wyse RK
    J Parkinsons Dis; 2013 Jan; 3(3):231-9. PubMed ID: 24018336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug Repurposing in Parkinson's Disease.
    Athauda D; Foltynie T
    CNS Drugs; 2018 Aug; 32(8):747-761. PubMed ID: 30066310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Linked Clinical Trials initiative (LCT) for Parkinson's disease.
    Brundin P; Wyse RK
    Eur J Neurosci; 2019 Feb; 49(3):307-315. PubMed ID: 30269406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations.
    Lang AE; Espay AJ
    Mov Disord; 2018 May; 33(5):660-677. PubMed ID: 29644751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2020.
    McFarthing K; Buff S; Rafaloff G; Dominey T; Wyse RK; Stott SRW
    J Parkinsons Dis; 2020; 10(3):757-774. PubMed ID: 32741777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disease-Modifying Drugs in Parkinson's Disease.
    Park A; Stacy M
    Drugs; 2015 Dec; 75(18):2065-71. PubMed ID: 26581672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Old wines in new bottles: Repurposing opportunities for Parkinson's disease.
    Kakkar AK; Singh H; Medhi B
    Eur J Pharmacol; 2018 Jul; 830():115-127. PubMed ID: 29689247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in drug development for Parkinson's disease: present status.
    Harikrishna Reddy D; Misra S; Medhi B
    Pharmacology; 2014; 93(5-6):260-71. PubMed ID: 25096413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring neuroprotection and restorative therapies in Parkinson's disease with PET.
    Brooks DJ
    J Neural Transm Suppl; 2000; (60):125-37. PubMed ID: 11205135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel therapeutic strategies in Parkinson's disease.
    Klivenyi P; Vecsei L
    Eur J Clin Pharmacol; 2010 Feb; 66(2):119-25. PubMed ID: 19834698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current management of Parkinson's disease.
    Salawu F; Olokoba A; Danburam A
    Ann Afr Med; 2010; 9(2):55-61. PubMed ID: 20587924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safinamide in the treatment of Parkinson's disease.
    Schapira AH
    Expert Opin Pharmacother; 2010 Sep; 11(13):2261-8. PubMed ID: 20707760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
    Fahn S;
    J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease-modifying strategies for Parkinson's disease.
    Kalia LV; Kalia SK; Lang AE
    Mov Disord; 2015 Sep; 30(11):1442-50. PubMed ID: 26208210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New small molecules for the treatment of Parkinson's disease.
    Müller T
    Expert Opin Investig Drugs; 2010 Sep; 19(9):1077-86. PubMed ID: 20645881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New treatments for the motor symptoms of Parkinson's disease.
    Vijverman AC; Fox SH
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):761-77. PubMed ID: 25318835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The current status of pharmacotherapy for the treatment of Parkinson's disease: transition from single-target to multitarget therapy.
    Cheong SL; Federico S; Spalluto G; Klotz KN; Pastorin G
    Drug Discov Today; 2019 Sep; 24(9):1769-1783. PubMed ID: 31102728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers of Parkinson's disease: present and future.
    Miller DB; O'Callaghan JP
    Metabolism; 2015 Mar; 64(3 Suppl 1):S40-6. PubMed ID: 25510818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent important trials of pharmacotherapy in Parkinson's disease.
    Doggrell SA
    Expert Opin Pharmacother; 2005 Jun; 6(6):1025-8. PubMed ID: 15952930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.